‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s
May 4, 2026
May 4, 2026
Health Canada has approved a second drug that can slow the progression of Alzheimer’s disease.
Donanemab, sold by American drugmaker Eli Lilly under the brand name Kisunla, received Health Canada approval on Monday, the company said in a press release.
It received approval from the U.S. Food and Drug Administration in 2024.
This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as “Leqembi,” in October 2025.
Donanemab, like lecanamab, targets amyloids — a sticky protein that develops in the brain in the early stages of Alzheimer’s disease. The buildup of amyloid plaques in the brain may lead to memory and thinking issues.
Read more: https://globalnews.ca/news/11828976/health-canada-second-drug-alzheimers/
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.